MannKind (MNKD) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, MNKD broke through the 20-day moving average, which suggests a ...

On Thursday, MannKind Corp (MNKD) stock saw a decline, ending the day at $6.44 which represents a decrease of $-0.05 or -0.77% from the prior close of $6.49. The stock opened at $6.47 and touched a ...

MannKind (MNKD), which belongs to the Zacks Medical - Biomedical and Genetics industry, could be a great candidate to consider. This biopharmaceutical company has seen a nice streak of beating ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

MannKind's stock has surged 73%, driven by its 9% royalty stake in United Therapeutics' Tyvaso DPI, which excels in the PAH market. In Q2 2024, MannKind's revenues rose 49% year-over-year to $72 ...

On Monday, MannKind Corp (MNKD) stock saw a modest uptick, ending the day at $6.82 which represents a slight increase of $0.28 or 4.28% from the prior close of $6.54. The stock opened at $6.58 and ...

(RTTNews) - MannKind (MNKD) reported top-level 30-week results from Phase 4 INHALE-3 study, in which additional patients living with type 1 diabetes achieved target A1c levels during the extension ...

Though most have underperformed in 2024, these 9 S&P 500 stocks offer a 5% dividend yield or better.